NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

Enrolling By InvitationPhase 2

Sponsor: Universidad Nacional Autonoma de Mexico

Conditions: Multiple Sclerosis Relapsing Remitting, Treatment

Interventions: IV Methylprednisolone administration, Nasal Methylprednisolone (MT)

Countries: Mexico

This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Age between 18 and 65 years.
* Diagnosis of RRMS with an evolution from diagnosis of 3 months to 10 years.
* Kurtzke Expanded Disability Status Scale (EDSS) from 1 to 6 (grade 6 includes patients with unilateral aid to ambulate)
* No contraindication for the administration of MP.
* Agree to participate in the study by means of a signed informed consent

Exclusion Criteria:

* Intake of anti-inflammatory steroids in the last 3 days.
* Patients with active bacterial, viral or fungal infections or undergoing treatment.
* Patients with hypertension.
* Patients with diabetes mellitus.
* Patients with hypo or hyperthyroidism.
* Patients with glaucoma.
* Patients with neoplasms.
* Diagnosis of systemic diseases such as: cardiovascular, pulmonary, hepatic, endocrine, gastrointestinal, etc.
* Patients with suspected or confirmed pregnancy by means of serum or urinary laboratory tests.
* Breastfeeding patients.
* Patients with a history of resistance to glucocorticoids.
* Patients with a history of severe adverse reactions to glucocorticoids.
* Patients with a history of hyposmia or anosmia.
* Patients diagnosed with active sinusitis.
* Patients with allergic rhinitis.
* Patients with upper respiratory tract infections.
* deviated septum
* History of nasal surgery.

Locations (1)

Mexico City, Mexico